Find My Journal

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

Luis Paz‐Ares, Tudor–Eliade Ciuleanu, Manuel Cobo, Michael Schenker, Bogdan Żurawski, J. Menezes, Eduardo Richardet, Jaafar Bennouna, Enriqueta Felip, Óscar Juan, Aurelia Alexandru, Hiroshi Sakai, Alejo Lingua, Pamela Salman, Pierre-Jean Souquet, Pedro De Marchi, Claudio Martín, M. Pérol, Arnaud Scherpereel, Shun Lü, Thomas John, David P. Carbone, S. Meadows–Shropshire, Shruti Agrawal, Abderrahim Oukessou, Jinchun Yan, Martin Reck

The Lancet Oncology, 2021

Hospital Universitario 12 De Octubre, Institute of Oncology Prof. Dr. Ion Chiricuta, Instituto de Investigación Biomédica de Málaga, Hospital Clínico Universitario Virgen de la Victoria, Hospital Nossa Senhora da Conceição, Instituto Oncológico de Córdoba, Inserm, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Hospital Universitari i Politècnic La Fe, Institutul Oncologic Bucuresti, Saitama Cancer Center, Instituto Médico Río Cuarto, Fundación Arturo López Pérez, Hôpital Lyon Sud, Hospital de Câncer de Barretos, Instituto Alexander Fleming, Centre de Recherche en Cancérologie de Lyon, Centre Hospitalier Universitaire de Lille, Université de Lille, Shanghai Chest Hospital, Shanghai Jiao Tong University, Austin Hospital, The Ohio State University, Bristol-Myers Squibb (United States), German Center for Lung Research

Publisher Website

Abstract

An abstract is not available for this record. Please visit the publisher website for more details.

1339

Citations

View on Google Scholar